Ladarixin

Overview

Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.

Application

Products | Products > Disease Areas > Arthritis | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-19519
• CAS No.: 849776-05-2
• Molecular Formula: C11H12F3NO6S2
• Molecular Weight: 375.34
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution
• Availability: In-stock

Source

Original product source